Michael Lehmann has left contract research organisation Covance to join Patheon as president of global pharmaceutical development services.
Patheon, which provides both contract development and manufacturing services to pharma companies, said that Lehmann’s appointment will help drive the company’s growth as it continues to transform its business amid varying marketing conditions.
This includes the company’s recent acquisition of speciality pharma firm Banner Pharmacaps for $255m.
“I am pleased to be welcoming Mike and getting him quickly integrated with Patheon’s leadership team,” stated James Mullen, Patheon’s CEO.
“He is a highly accomplished senior executive with a proven track record in the healthcare, life sciences and drug development sectors.”
Lehmann’s most recent role was corporate senior VP and general manager of the global early development business of the contract research organisation (CRO) Covance.
During his time in this role, he helped Covance secure deals with both Lilly and Sanofi.
Prior to joining Covance, Lehmann spent 17 years at GE Healthcare in several senior roles, including general manager of multivendor services.